Center for Health Technology Assessment and Pharmacoeconomics Research, Faculty of Pharmacy, University of Pécs, Pécs, Hungary.
Syreon Research Institute, Budapest, Hungary.
Front Public Health. 2023 Apr 26;11:1088121. doi: 10.3389/fpubh.2023.1088121. eCollection 2023.
Artificial intelligence (AI) has attracted much attention because of its enormous potential in healthcare, but uptake has been slow. There are substantial barriers that challenge health technology assessment (HTA) professionals to use AI-generated evidence for decision-making from large real-world databases (e.g., based on claims data). As part of the European Commission-funded HTx H2020 (Next Generation Health Technology Assessment) project, we aimed to put forward recommendations to support healthcare decision-makers in integrating AI into the HTA processes. The barriers, addressed by the paper, are particularly focusing on Central and Eastern European (CEE) countries, where the implementation of HTA and access to health databases lag behind Western European countries.
We constructed a survey to rank the barriers to using AI for HTA purposes, completed by respondents from CEE jurisdictions with expertise in HTA. Using the results, two members of the HTx consortium from CEE developed recommendations on the most critical barriers. Then these recommendations were discussed in a workshop by a wider group of experts, including HTA and reimbursement decision-makers from both CEE countries and Western European countries, and summarized in a consensus report.
Recommendations have been developed to address the top 15 barriers in areas of (1) human factor-related barriers, focusing on educating HTA doers and users, establishing collaborations and best practice sharing; (2) regulatory and policy-related barriers, proposing increasing awareness and political commitment and improving the management of sensitive information for AI use; (3) data-related barriers, suggesting enhancing standardization and collaboration with data networks, managing missing and unstructured data, using analytical and statistical approaches to address bias, using quality assessment tools and quality standards, improving reporting, and developing better conditions for the use of data; and (4) technological barriers, suggesting sustainable development of AI infrastructure.
In the field of HTA, the great potential of AI to support evidence generation and evaluation has not yet been sufficiently explored and realized. Raising awareness of the intended and unintended consequences of AI-based methods and encouraging political commitment from policymakers is necessary to upgrade the regulatory and infrastructural environment and knowledge base required to integrate AI into HTA-based decision-making processes better.
人工智能(AI)因其在医疗保健领域的巨大潜力而备受关注,但采用速度缓慢。对于健康技术评估(HTA)专业人员来说,使用基于大型真实世界数据库(例如,基于索赔数据)的 AI 生成证据进行决策存在着重大障碍。作为欧盟委员会资助的 HTx H2020(下一代健康技术评估)项目的一部分,我们旨在提出建议,以支持医疗保健决策者将 AI 纳入 HTA 流程。本文所解决的障碍特别针对中东欧(CEE)国家,这些国家在 HTA 的实施和获取健康数据库方面落后于西欧国家。
我们构建了一份调查来对阻碍将 AI 用于 HTA 目的的障碍进行排名,由 CEE 司法管辖区的 HTA 专家完成。使用调查结果,来自 CEE 的 HTx 联盟的两名成员针对最关键的障碍制定了建议。然后,来自 CEE 国家和西欧国家的 HTA 和报销决策者在一次专题研讨会上讨论了这些建议,并在一份共识报告中进行了总结。
在以下领域制定了针对前 15 个障碍的建议:(1)与人相关的障碍领域,重点是对 HTA 从业者和用户进行教育,建立合作关系和最佳实践共享;(2)监管和政策相关的障碍领域,建议提高认识和政治承诺,并改进 AI 用途的敏感信息管理;(3)数据相关的障碍领域,建议加强标准化和与数据网络的合作,管理缺失和非结构化数据,使用分析和统计方法解决偏差,使用质量评估工具和质量标准,改善报告,并为数据的使用创造更好的条件;(4)技术相关的障碍领域,建议可持续发展 AI 基础设施。
在 HTA 领域,AI 在支持证据生成和评估方面的巨大潜力尚未得到充分探索和实现。提高对基于 AI 的方法的预期和非预期后果的认识,并鼓励政策制定者做出政治承诺,对于升级整合 AI 进入基于 HTA 的决策过程所需的监管和基础设施环境以及知识库是必要的。